European Commission approves JASCAYD for fibrotic lung diseases across the EU
Question
European Commission approves JASCAYD for fibrotic lung diseases across the EU
Direct answer
Positive for the developer’s and European biotech valuations, with read‑through to EU healthcare indices; may influence healthcare M&A expectations and sector rotation within STOXX Europe benchmarks.
- Original publisher
- Market Ontology
- Evidence through
- 2026-07-17
- Published
- 2026-10-20
- Revision
- 1 · 2026-10-20
Cite as: Market Ontology, “European Commission approves JASCAYD for fibrotic lung diseases across the EU”, revision 1, evidence through 2026-07-17. https://marketontology.com/market-events/2026-07-17/european-commission-approves-jascayd-for-fibrotic-lung-diseases-across-the-eu-9865f8
Does this development affect your holdings?
Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.
Review your initial audit before choosing ongoing portfolio scanning at $79/month.
What happened next
| Asset | Call | Base close | +1 day | +5 days | +20 days |
|---|---|---|---|---|---|
| XBI | Watch | 154.26 2026-07-17 | -2.15% | -2.45% | +2.04% |
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
Sources
Related
- 2026-10-19Viking Therapeutics raises $575M via equity and convertible notesVKTX XBI
- 2026-10-19Zentalis Reports 15.8-Month Median OS for Azenosertib at ESMO CongressXBI ZNTL
- 2026-10-19Zentalis Reports 15.8-Month Median OS for Azenosertib at ESMO CongressXBI
- 2026-10-19Viking Therapeutics raises $575M via equity and convertible notesXBI
- 2026-10-06Spyre Therapeutics Prices $350 Million Public Equity Offering at $85 Per ShareSYRE XBI
- 2026-10-04Genmab Reports 45.9% Response Rate in Phase 2 Ovarian Cancer Antibody-Drug TrialGMAB XBI
- 2026-09-25ADARx Pharmaceuticals Prices Upsized $446.3M Initial Public Offering at $17ADRX XBI-3.04%
- 2026-09-25ADARx Pharmaceuticals Prices Upsized $446.3M Initial Public Offering at $17XBI-0.39%
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.